{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:12:23Z","timestamp":1782414743542,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:00:00Z","timestamp":1382054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2013.50","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T13:13:47Z","timestamp":1382102027000},"page":"e153-e153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B"],"prefix":"10.1038","volume":"3","author":[{"given":"J-Y","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Szwajcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ishdorj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Benjaminson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J B","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S B","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,18]]},"reference":[{"key":"BFbcj201350_CR1","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood-2005-02-0819","volume":"107","author":"E Montserrat","year":"2006","unstructured":"Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gin\u00e9 E, Bosch F . How I treat refractory CLL. Blood 2006; 107: 1276\u20131283.","journal-title":"Blood"},{"key":"BFbcj201350_CR2","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1080\/1042819021000006547","volume":"43","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755\u20131762.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201350_CR3","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/cncr.24329","volume":"115","author":"A-M Tsimberidou","year":"2009","unstructured":"Tsimberidou A-M, Keating MJ . Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009; 115: 2824\u20132836.","journal-title":"Cancer"},{"key":"BFbcj201350_CR4","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","volume":"117","author":"XC Badoux","year":"2011","unstructured":"Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016\u20133024.","journal-title":"Blood"},{"key":"BFbcj201350_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","volume":"102","author":"JL Aron","year":"2003","unstructured":"Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8\u2013mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003; 102: 652\u2013658.","journal-title":"Blood"},{"key":"BFbcj201350_CR6","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","volume":"11","author":"S Inoue","year":"2004","unstructured":"Inoue S, MacFarlane M, Harper N, Wheat LMC, Dyer MJS, Cohen GM . Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11: S193\u2013S206.","journal-title":"Cell Death Differ"},{"key":"BFbcj201350_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/sj.leu.2404760","volume":"21","author":"S Inoue","year":"2007","unstructured":"Inoue S, Riley J, Gant TW, Dyer MJS, Cohen GM . Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007; 21: 1773\u20131782.","journal-title":"Leukemia"},{"key":"BFbcj201350_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.leu.2403388","volume":"18","author":"DM Lucas","year":"2004","unstructured":"Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004; 18: 1207\u20131214.","journal-title":"Leukemia"},{"key":"BFbcj201350_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959\u2013967.","journal-title":"Blood"},{"key":"BFbcj201350_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","volume":"147","author":"KA Blum","year":"2009","unstructured":"Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009; 147: 507\u2013514.","journal-title":"Br J Haematol"},{"key":"BFbcj201350_CR11","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969\u20136978.","journal-title":"EMBO J"},{"key":"BFbcj201350_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","volume":"64","author":"N Gurvich","year":"2004","unstructured":"Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS . Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079\u20131086.","journal-title":"Cancer Res"},{"key":"BFbcj201350_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nbt.1759","volume":"29","author":"M Bantscheff","year":"2011","unstructured":"Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon A-M et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotech 2011; 29: 255\u2013265.","journal-title":"Nat Biotech"},{"key":"BFbcj201350_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07426.x","volume":"144","author":"AB Bouzar","year":"2009","unstructured":"Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 41\u201352.","journal-title":"Br J Haematol"},{"key":"BFbcj201350_CR15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.exphem.2007.06.014","volume":"35","author":"L Lagneaux","year":"2007","unstructured":"Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M et al. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 2007; 35: 1527\u20131537.","journal-title":"Exp Hematol"},{"key":"BFbcj201350_CR16","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/leu.2009.176","volume":"23","author":"B Stamatopoulos","year":"2009","unstructured":"Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009; 23: 2281\u20132289.","journal-title":"Leukemia"},{"key":"BFbcj201350_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2119\/2007-00084.Bokelmann","volume":"14","author":"I Bokelmann","year":"2008","unstructured":"Bokelmann I, Mahlknecht U . Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 2008; 14: 20\u201327.","journal-title":"Mol Med"},{"key":"BFbcj201350_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/14656566.9.2.285","volume":"9","author":"T Gerstner","year":"2008","unstructured":"Gerstner T, Bell N, K\u00f6nig S . Oral valproic acid for epilepsy: long-term experience in therapy and side effects. Expert Opin Pharmacother 2008; 9: 285\u2013292.","journal-title":"Expert Opin Pharmacother"},{"key":"BFbcj201350_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E . Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695\u2013714.","journal-title":"CNS Drugs"},{"key":"BFbcj201350_CR20","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/sj.leu.2403717","volume":"19","author":"C Paquet","year":"2005","unstructured":"Paquet C, Sane AT, Beauchemin M, Bertrand R . Caspase- and mitochondrial dysfunction-dependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis. Leukemia 2005; 19: 784\u2013791.","journal-title":"Leukemia"},{"key":"BFbcj201350_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1158\/1535-7163.MCT-04-0301","volume":"4","author":"L Emert-Sedlak","year":"2005","unstructured":"Emert-Sedlak L, Shangary S, Rabinovitz A, Miranda MB, Delach SM, Johnson DE . Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. Mol Cancer Ther 2005; 4: 733\u2013742.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201350_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10059-011-1032-4","volume":"31","author":"S Cho","year":"2011","unstructured":"Cho S, Park J, Hwang E . Kinetics of the cell biological changes occurring in the progression of DNA damage-induced senescence. Mol Cells 2011; 31: 539\u2013546.","journal-title":"Mol Cells"},{"key":"BFbcj201350_CR23","doi-asserted-by":"publisher","first-page":"6434","DOI":"10.1038\/onc.2008.310","volume":"27","author":"P Boya","year":"2008","unstructured":"Boya P, Kroemer G . Lysosomal membrane permeabilization in cell death. Oncogene 2008; 27: 6434\u20136451.","journal-title":"Oncogene"},{"key":"BFbcj201350_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbapap.2011.08.016","volume":"1824","author":"U Repnik","year":"2012","unstructured":"Repnik U, Stoka V, Turk V, Turk B . Lysosomes and lysosomal cathepsins in cell death. Biochim Biophys Acta 2012; 1824: 22\u201333.","journal-title":"Biochim Biophys Acta"},{"key":"BFbcj201350_CR25","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1093\/emboj\/20.17.4629","volume":"20","author":"V Turk","year":"2001","unstructured":"Turk V, Turk B, Turk D . Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001; 20: 4629\u20134633.","journal-title":"EMBO J"},{"key":"BFbcj201350_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/ncb2171","volume":"13","author":"PA Kreuzaler","year":"2011","unstructured":"Kreuzaler PA, Staniszewska AD, Li W, Omidvar N, Kedjouar B, Turkson J et al. Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol 2011; 13: 303\u2013309.","journal-title":"Nat Cell Biol"},{"key":"BFbcj201350_CR27","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1074\/jbc.M508533200","volume":"281","author":"BHY Yeung","year":"2006","unstructured":"Yeung BHY, Huang D-C, Sinicrope FA . PS-341 (Bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006; 281: 11923\u201311932.","journal-title":"J Biol Chem"},{"key":"BFbcj201350_CR28","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.bcp.2010.07.036","volume":"80","author":"S Bien","year":"2010","unstructured":"Bien S, Rimmbach C, Neumann H, Niessen J, Reimer E, Ritter CA et al. Doxorubicin-induced cell death requires cathepsin B in HeLa cells. Biochem Pharmacol 2010; 80: 1466\u20131477.","journal-title":"Biochem Pharmacol"},{"key":"BFbcj201350_CR29","doi-asserted-by":"publisher","first-page":"17196","DOI":"10.1074\/jbc.M413744200","volume":"280","author":"TA Taha","year":"2005","unstructured":"Taha TA, Kitatani K, Bielawski J, Cho W, Hannun YA, Obeid LM . Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 2005; 280: 17196\u201317202.","journal-title":"J Biol Chem"},{"key":"BFbcj201350_CR30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1172\/JCI9914","volume":"106","author":"ME Guicciardi","year":"2000","unstructured":"Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C . Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000; 106: 1127\u20131137.","journal-title":"J Clin Invest"},{"key":"BFbcj201350_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.chembiol.2009.07.011","volume":"16","author":"MR Pratt","year":"2009","unstructured":"Pratt MR, Sekedat MD, Chiang KP, Muir TW . Direct measurement of cathepsin B activity in the cytosol of apoptotic cells by an activity-based probe. Chem Biol 2009; 16: 1001\u20131012.","journal-title":"Chem Biol"},{"key":"BFbcj201350_CR32","doi-asserted-by":"publisher","first-page":"19140","DOI":"10.1074\/jbc.M802513200","volume":"283","author":"G Droga-Mazovec","year":"2008","unstructured":"Droga-Mazovec G, Boji\u010d L, Petelin A, Ivanova S, Romih R, Repnik U et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. J Biol Chem 2008; 283: 19140\u201319150.","journal-title":"J Biol Chem"},{"key":"BFbcj201350_CR33","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.1038\/sj.onc.1207004","volume":"22","author":"JB Johnston","year":"2003","unstructured":"Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM et al. Role of the TRAIL\/\/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003; 22: 8356\u20138369.","journal-title":"Oncogene"},{"key":"BFbcj201350_CR34","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi C, Nicoletti I . Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1: 1458\u20131461.","journal-title":"Nat Protoc"},{"key":"BFbcj201350_CR35","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990\u20134997.","journal-title":"Blood"},{"key":"BFbcj201350_CR36","doi-asserted-by":"publisher","first-page":"18851","DOI":"10.1074\/jbc.M312795200","volume":"279","author":"DC Lagace","year":"2004","unstructured":"Lagace DC, Nachtigal MW . Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 2004; 279: 18851\u201318860.","journal-title":"J Biol Chem"},{"key":"BFbcj201350_CR37","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/1535-7163.MCT-09-1000","volume":"9","author":"V El-Khoury","year":"2010","unstructured":"El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NHC et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010; 9: 1349\u20131360.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201350_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.nutr.27.061406.093749","volume":"27","author":"N Mizushima","year":"2007","unstructured":"Mizushima N, Klionsky DJ . Protein turnover via autophagy: implications for metabolism*. Annu Rev Nutr 2007; 27: 19\u201340.","journal-title":"Annu Rev Nutr"},{"key":"BFbcj201350_CR39","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2010.11.012","volume":"143","author":"MJ Clague","year":"2010","unstructured":"Clague MJ, Urb\u00e9 S . Ubiquitin: same molecule, different degradation pathways. Cell 2010; 143: 682\u2013685.","journal-title":"Cell"},{"key":"BFbcj201350_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.cdd.4401160","volume":"10","author":"U Fischer","year":"2003","unstructured":"Fischer U, Janicke RU, Schulze-Osthoff K . Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003; 10: 76\u2013100.","journal-title":"Cell Death Differ"},{"key":"BFbcj201350_CR41","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/cdd.2009.184","volume":"17","author":"TV Berghe","year":"2010","unstructured":"Berghe TV, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 2010; 17: 922\u2013930.","journal-title":"Cell Death Differ"},{"key":"BFbcj201350_CR42","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines. Blood 2008; 111: 5446\u20135456.","journal-title":"Blood"},{"key":"BFbcj201350_CR43","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.4049\/jimmunol.1100532","volume":"187","author":"B Vire","year":"2011","unstructured":"Vire B, David A, TOSO Wiestner A . The Fc\u03bc receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to tlr activation. J Immunol 2011; 187: 4040\u20134050.","journal-title":"J Immunol"},{"key":"BFbcj201350_CR44","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","volume":"118","author":"SH Lim","year":"2011","unstructured":"Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118: 2530\u20132540.","journal-title":"Blood"},{"key":"BFbcj201350_CR45","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1182\/blood-2011-01-331702","volume":"118","author":"M Jak","year":"2011","unstructured":"Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 monoclonal antibody GA101. Blood 2011; 118: 5178\u20135188.","journal-title":"Blood"},{"key":"BFbcj201350_CR46","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1182\/blood-2009-10-246199","volume":"116","author":"K Balakrishnan","year":"2010","unstructured":"Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG et al. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 2010; 116: 1083\u20131091.","journal-title":"Blood"},{"key":"BFbcj201350_CR47","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.tiv.2011.04.019","volume":"25","author":"E Rudolf","year":"2011","unstructured":"Rudolf E, \u010cervinka M . Sulforaphane induces cytotoxicity and lysosome- and mitochondria-dependent cell death in colon cancer cells with deleted p53. Toxicol In Vitro 2011; 25: 1302\u20131309.","journal-title":"Toxicol In Vitro"},{"key":"BFbcj201350_CR48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/bjc.2011.42","volume":"104","author":"V Cheriyath","year":"2011","unstructured":"Cheriyath V, Kuhns MA, Kalaycio ME, Borden EC . Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer 2011; 104: 957\u2013967.","journal-title":"Br J Cancer"},{"key":"BFbcj201350_CR49","doi-asserted-by":"publisher","first-page":"G947","DOI":"10.1152\/ajpgi.00151.2002","volume":"283","author":"NW Werneburg","year":"2002","unstructured":"Werneburg NW, Guicciardi ME, Bronk SF, Gores GJ . Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol 2002; 283: G947\u2013G956.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"BFbcj201350_CR50","first-page":"171","volume":"20","author":"P Meusers","year":"1977","unstructured":"Meusers P, K\u00f6nig E, Fink U, Brittinger G . Lysosomal acid hydrolases in isolated normal and chronic lymphocytic leukemia (CLL) T- and B-lymphocytes. Haematol Blood Transfus 1977; 20: 171\u2013174.","journal-title":"Haematol Blood Transfus"},{"key":"BFbcj201350_CR51","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1002\/1097-0142(19801215)46:12<2676::AID-CNCR2820461223>3.0.CO;2-L","volume":"46","author":"D Schmidt","year":"1980","unstructured":"Schmidt D, Radzun H, Schwarze E, Stein H, Parwaresch M . Activity and isoenzymes of acid phosphatase in human B-cell lymphomas of low-grade malignancy: a novel aid in the classification of malignant lymphoma. Cancer 1980; 46: 2676\u20132681.","journal-title":"Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bcj201350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bcj201350","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:46:29Z","timestamp":1672958789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,18]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10]]}},"alternative-id":["BFbcj201350"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2013.50","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,18]]},"assertion":[{"value":"21 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}